{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:02:51Z","timestamp":1790352171810,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015872","name":"Universit\u00e9 de Lille","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004795","name":"French Universities Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010095","name":"Hauts-de-France Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["Click & Detect, CE29, 2024"],"award-info":[{"award-number":["Click & Detect, CE29, 2024"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular & Cellular Proteomics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.mcpro.2026.101639","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:26:04Z","timestamp":1786577164000},"page":"101639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clone-By-Clone Therapy Guidance in Luminal Breast Cancer Via Spatial Proteomics and Patient-Derived Tumoroid"],"prefix":"10.1016","volume":"25","author":[{"given":"Laurine","family":"Lagache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Raffo-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-5605","authenticated-orcid":false,"given":"Marie","family":"Duhamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanis","family":"Zirem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maire","family":"Vanseymortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-5044","authenticated-orcid":false,"given":"Isabelle","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawale","family":"Hajjaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4318-0817","authenticated-orcid":false,"given":"Michel","family":"Salzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2026.101639_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mcpro.2026.101639_bib2","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1093\/nar\/gkad666","article-title":"Deciphering a global source of non-genetic heterogeneity in cancer cells","volume":"51","author":"Zhang","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mcpro.2026.101639_bib3","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1111\/febs.13705","article-title":"Intra-tumor heterogeneity \u2013 going beyond genetics","volume":"283","author":"Caiado","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.mcpro.2026.101639_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2026.101639_bib5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ccell.2025.05.003","article-title":"The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets","volume":"43","author":"Knol","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mcpro.2026.101639_bib6","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2026.101639_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41586-021-03357-x","article-title":"Breast tumours maintain a reservoir of subclonal diversity during expansion","volume":"592","author":"Minussi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2026.101639_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2024.103068","article-title":"Mass spectrometry imaging methods for visualizing tumor heterogeneity","volume":"86","author":"Duncan","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.mcpro.2026.101639_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41576-020-0265-5","article-title":"Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics","volume":"22","author":"Nam","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.mcpro.2026.101639_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.802177","article-title":"Path to clonal theranostics in luminal breast cancers","volume":"11","author":"Hajjaji","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mcpro.2026.101639_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","article-title":"Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies","volume":"8","author":"Shi","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.mcpro.2026.101639_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103536","article-title":"Protocol for generating a co-culture of macrophages with breast cancer tumoroids","volume":"6","author":"Raffo-Romero","year":"2025","journal-title":"STAR Protoc."},{"key":"10.1016\/j.mcpro.2026.101639_bib13","doi-asserted-by":"crossref","first-page":"100792","DOI":"10.1016\/j.crmeth.2024.100792","article-title":"A co-culture system of macrophages with breast cancer tumoroids to study cell interactions and therapeutic responses","volume":"4","author":"Raffo-Romero","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.mcpro.2026.101639_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mcpro.2026.101639_bib15","first-page":"1351","article-title":"Patient-derived organoids in precision cancer medicine","volume":"5","author":"Tong","year":"2024","journal-title":"Med (N. Y)"},{"key":"10.1016\/j.mcpro.2026.101639_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2026.101639_bib17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.trechm.2025.09.002","article-title":"MS-based spatial proteomics: deciphering tissue microenvironment by bridging MS imaging and large-scale proteomics","volume":"7","author":"Goossen","year":"2025","journal-title":"Trends Chem."},{"key":"10.1016\/j.mcpro.2026.101639_bib18","article-title":"Predicting protein pathways associated to tumor heterogeneity by correlating spatial lipidomics and proteomics: the dry proteomic concept","volume":"24","author":"Lagache","year":"2024","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2026.101639_bib19","article-title":"K-Means++: the advantages of careful seeding","volume":"8","author":"Arthur","year":"2027"},{"key":"10.1016\/j.mcpro.2026.101639_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101482","article-title":"Real-time glioblastoma tumor microenvironment assessment by SpiderMass for improved patient management","author":"Zirem","year":"2024","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.mcpro.2026.101639_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41592-020-00998-0","article-title":"diaPASEF: parallel accumulation\u2013serial fragmentation combined with data-independent acquisition","volume":"17","author":"Meier","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.mcpro.2026.101639_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","article-title":"DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput","volume":"17","author":"Demichev","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.mcpro.2026.101639_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btaf644","article-title":"Profiler: an open web platform for multi-omics analysis","volume":"42","author":"Zirem","year":"2026","journal-title":"Bioinformatics"},{"key":"10.1016\/j.mcpro.2026.101639_bib24","doi-asserted-by":"crossref","first-page":"100128","DOI":"10.1016\/j.xcrm.2020.100128","article-title":"The clinical kinase index: a method to prioritize understudied kinases as drug targets for the treatment of cancer","volume":"1","author":"Essegian","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.mcpro.2026.101639_bib25","series-title":"TChem v2.0 - A Software Toolkit for The Analysis of Complex Kinetic Models","author":"Kim","year":"2020"},{"key":"10.1016\/j.mcpro.2026.101639_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrd.2018.14","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mcpro.2026.101639_bib27","article-title":"Unveiling the role of Tdark genes in genetic diseases and phenotypes through bioinformatics-based functional enrichment and network analyses","author":"Kafita","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.mcpro.2026.101639_bib28","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms25084507","article-title":"Comprehensive research on druggable proteins: from PSSM to pre-trained Language models","volume":"25","author":"Chu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcpro.2026.101639_bib29","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.bjc.6603350","article-title":"Fatty acid synthase: a novel target for antiglioma therapy","volume":"95","author":"Zhao","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mcpro.2026.101639_bib30","article-title":"Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: results from the targeted agent and profiling utilization registry Study","volume":"8","author":"Calfa","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.mcpro.2026.101639_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clbc.2021.05.009","article-title":"A phase II Study evaluating the safety and efficacy of sunitinib malate in combination with weekly paclitaxel followed by Doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy for locally advanced or inflammatory breast cancer","volume":"22","author":"Symonds","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.mcpro.2026.101639_bib32","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.7150\/thno.36338","article-title":"CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1\/P50","volume":"9","author":"Chi","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.mcpro.2026.101639_bib33","article-title":"Paclitaxel resistance in breast cancer: current challenges and recent advanced therapeutic strategies","volume":"43","author":"Abouzeid","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.mcpro.2026.101639_bib34","doi-asserted-by":"crossref","first-page":"9806","DOI":"10.1080\/21655979.2021.1995575","article-title":"Carbonic anhydrase 12 gene silencing reverses the sensitivity of paclitaxel in drug-resistant breast cancer cells","volume":"12","author":"Huang","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.mcpro.2026.101639_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41420-020-00322-x","article-title":"EDIL3 promotes epithelial-mesenchymal transition and paclitaxel resistance through its interaction with integrin \u03b1V\u03b23 in cancer cells","volume":"6","author":"Gasca","year":"2020","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.mcpro.2026.101639_bib36","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/bjc.2015.114","article-title":"Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer","volume":"112","author":"Sun","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mcpro.2026.101639_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11010-013-1939-5","article-title":"Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231","volume":"389","author":"Kr\u0229towski","year":"2014","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.mcpro.2026.101639_bib38","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1158\/1078-0432.CCR-09-3293","article-title":"A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes","volume":"16","author":"Jones","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2026.101639_bib39","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1021\/acs.molpharmaceut.4c01283","article-title":"Nanoparticle albumin-bound bortezomib: enhanced antitumor efficacy and tumor accumulation in breast cancer therapy","volume":"22","author":"Poor","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.mcpro.2026.101639_bib40","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.21037\/atm.2018.10.26","article-title":"Dasatinib in breast cancer: Src-ing for response in all the wrong kinases","volume":"6","author":"Kennedy","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.mcpro.2026.101639_bib41","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41416-018-0287-3","article-title":"Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells","volume":"119","author":"Tian","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mcpro.2026.101639_bib42","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.2147\/DDDT.S521260","article-title":"Dasatinib Dose optimization based on therapeutic drug monitoring in patients with chronic-phase chronic Myeloid leukemia","volume":"19","author":"Cheng","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.mcpro.2026.101639_bib43","article-title":"Paclitaxel\u2019s mechanistic and clinical effects on breast cancer","volume":"9","author":"Samaan","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.mcpro.2026.101639_bib44","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3109\/10717544.2014.999960","article-title":"Drug Delivery Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7 Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7","volume":"23","author":"Gandhi","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.mcpro.2026.101639_bib45","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","article-title":"Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"26","author":"Burstein","year":"2008","journal-title":"J. Clin. Oncol."}],"container-title":["Molecular & Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947626001350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947626001350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:10:03Z","timestamp":1790349003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947626001350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1535947626001350"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2026.101639","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clone-By-Clone Therapy Guidance in Luminal Breast Cancer Via Spatial Proteomics and Patient-Derived Tumoroid","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2026.101639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101639"}}